Migraine attacks often strike without warning, bringing intense pain, light sensitivity and nausea. Traditional acute treatments have been limited, and preventive regimens usually require daily medication that many patients find difficult to tolerate. Rimegepant, marketed as Nurtec ODT, introduces a different approach by blocking calcitonin gene‑related peptide (CGRP) receptors, a protein involved in migraine pain pathways. The drug is formulated as an orally dissolving tablet that can be placed on or under the tongue, allowing patients who are nauseated or vomiting to still receive a dose.
The U.S. Food and Drug Administration first approved rimegepant in February 2020 for the acute treatment of migraine, marking the first approval of a CGRP‑targeting agent for this indication. In June 2021 the FDA broadened the label to include prophylaxis of episodic migraine, making it one of the few medications authorized for both acute relief and prevention.
International approvals have followed, though at a slower pace. The United Arab Emirates and Israel granted approval in March 2021. The United Kingdom’s National Institute for Health and Care Excellence (NICE) subsequently endorsed the drug for both acute and preventive use. Canada became the most recent market to authorize rimegepant in December 2023, after Health Canada reviewed the same clinical data accepted by regulators in the United States, United Kingdom and UAE.
Migraine affects roughly one in seven people worldwide, and many patients do not achieve adequate relief from existing therapies. Standard acute drugs such as triptans work by constricting blood vessels, which can be unsafe for individuals with cardiovascular disease or uncontrolled hypertension. Rimegepant does not cause vascular constriction, thereby expanding treatment possibilities for this subgroup.
Rimegepant’s development reflects a shift in migraine therapeutics. Early CGRP inhibitors were injectable monoclonal antibodies administered monthly or quarterly. In contrast, rimegepant is a small‑molecule oral formulation that reaches the bloodstream quickly, provides relief within hours, and is eliminated relatively fast, eliminating the need for injections or large‑volume pills.
Clinical trials that supported regulatory approvals demonstrated statistically significant improvements over placebo in both pain relief and resolution of the most bothersome migraine symptoms—photophobia, phonophobia and nausea. While the effect sizes were modest, they were meaningful for patients who often experience little to no benefit from other medications.
In Canada, the new approval arrives amid uneven access to migraine specialists and delayed availability of novel therapies compared with the United States. Provincial drug plans and private insurers will determine how widely patients can obtain the medication.
Like all medicines, rimegepant carries potential side effects. Reported adverse events include nausea, abdominal pain and dyspepsia, and rare serious allergic reactions have been noted. Cost remains a significant barrier; the U.S. list price exceeds $900 for an eight‑tablet pack, and coverage varies across insurance plans. Biohaven Pharmaceuticals, the original developer, and Pfizer— which acquired the drug in an $11.6 billion transaction— have worked to secure broad reimbursement, yet affordability continues to challenge many sufferers.
Each regulatory endorsement reflects a judgment that the therapeutic benefits outweigh the risks for the intended population. For patients who have exhausted triptans, anti‑nausea agents and preventive drugs that cause fatigue or weight gain, rimegepant offers an additional option. Although migraine remains incurable, a single formulation that can both abort an ongoing attack and reduce the frequency of future episodes is uncommon.
The Canadian approval in December 2023 marks the latest milestone in rimegepant’s global rollout, and further authorizations are anticipated as clinicians and payers assess its role within the expanding migraine treatment landscape.
